ArticleBMC biotechnology2026
Quercetin-loaded PCL scaffold suppresses bone metastatic tumors and augments in situ bone formation.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study developed a dual-functional 3D-printed poly(ε-caprolactone) (PCL) scaffold loaded with quercetin (Q-PCL) for synergistic inhibition of bone metastatic tumors and promotion of bone regeneration. The scaffold was fabricated via melt extrusion, exhibiting a uniform porous structure conducive to sustained quercetin release. In vitro, Q-PCL significantly suppressed renal carcinoma (RENCA) cell proliferation and induced apoptosis, while enhancing the osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells (BMSCs). In a murine subcutaneous tumor model, Q-PCL implantation effectively inhibited tumor growth via apoptosis induction without systemic toxicity. In a rat femoral defect model, the scaffold markedly accelerated bone repair, showing increased bone volume, improved trabecular morphology, and mature bone formation. The Q-PCL scaffold demonstrates great potential as a localized co-therapy strategy for treating osteolytic bone metastases and facilitating bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.